Loading
KIF5B (Kinesin-1 heavy chain) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.
Microtubule-dependent motor required for normal distribution of mitochondria and lysosomes. Can induce formation of neurite-like membrane protrusions in non-neuronal cells in a ZFYVE27-dependent manner. Regulates centrosome and nuclear positioning during mitotic entry.
Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes clinical 0.97, affected pathway 0.93, literature 0.91, genetic association 0.00, somatic mutation 0.82). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Head and Neck Squamous Cell Carcinoma.
In plain words · KIF5B (Kinesin-1 heavy chain) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.
KIF5B (Kinesin-1 heavy chain) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.
Microtubule-dependent motor required for normal distribution of mitochondria and lysosomes. Can induce formation of neurite-like membrane protrusions in non-neuronal cells in a ZFYVE27-dependent manner.
No product in this corpus aims at KIF5B yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA KIF5B: RNA low tissue specificity; high antibody staining in 19 normal tissues; highest cancer staining pancreatic cancer (7 of 11 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Thyroid cancer, Neuroendocrine tumours, Head and neck squamous cell carcinoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (non-small cell lung carcinoma, medullary thyroid gland carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P33176; IntOGen KIF5B; Human Protein Atlas KIF5B tissue; Open Targets ENSG00000170759 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Navone et al, J. Cell Biol, 1992, "Cloning and expression of a human kinesin heavy chain gene: interaction of the COOH-terminal domain with cytoplasmic microtubules in transfected CV-1 cells". Source.
Sources: HGNC HGNC:6324 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P33176 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000170759 (association with cancer (MONDO_0004992) 0.81; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.72, thyroid cancer 0.64, neuroendocrine neoplasm 0.63, lung cancer 0.73 (GraphQL API, CC0)); IntOGen KIF5B (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Microtubule-dependent motor required for normal distribution of mitochondria and lysosomes. Can induce formation of neurite-like membrane protrusions in non-neuronal cells in a ZFYVE27-dependent manner. Regulates centrosome and nuclear positioning during mitotic entry. During the G2 phase of the cell cycle in a BICD2-dependent manner, antagonises dynein function and drives the separation of nuclei and centrosomes. Required for anterograde axonal transportation of MAPK8IP3/JIP3 which is essential for MAPK8IP3/JIP3 function in axon elongation. Through binding with PLEKHM2 and ARL8B, directs lysosome movement toward microtubule plus ends. Location: Cytoplasm, cytoskeleton; Cytolytic granule membrane; Lysosome membrane (UniProt). Locus 10p11.22 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Bone marrow, Breast, Caudate, Cervix, Epididymis, Liver, Lung, Lymph node.
Medium only: carcinoid, liver cancer, lymphoma, prostate cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KIF5B" OR ABSTRACT:"KIF5B" OR TITLE:"kinesin family member 5B" OR ABSTRACT:"kinesin family member 5B" OR TITLE:"Kinesin-1 heavy chain" OR ABSTRACT:"Kinesin-1 heavy chain" OR TITLE:"uKHC" OR ABSTRACT:"uKHC" OR TITLE:"KNS1" OR ABSTRACT:"KNS1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KIF5B, not a curated reading list.
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Lung cancer (all types).
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Open Targets Platform.
Shares Thyroid cancer, Lung cancer (all types), Open Targets Platform, Non-small-cell lung cancer.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.